immatics Closes EUR 34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

Tuesday, October 15, 2013 1 min read

Key Takeaway: immatics Closes EUR 34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

Full Press Release Details

immatics Closes EUR 34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer.